Form 4: Theravance Biopharma CEO Acquires Shares in Late Filing

Theravance Biopharma's CEO, Rick E. Winningham, acquired 3,193 ordinary shares at $9.57 per share, in a transaction reported late due to an administrative error.

Summary

• Rick E. Winningham, CEO of Theravance Biopharma, acquired 3,193 ordinary shares on November 14, 2024, at a price of $9.57 per share.
• The transaction was made directly with the issuer under the company's equity incentive plan and was not an open market purchase.
• The filing of this transaction was delayed due to an inadvertent administrative error.
• Following the transaction, Mr. Winningham directly owns 1,827,092 ordinary shares and indirectly owns 3,900 shares as custodian and 92,567 shares by trust.

Sentiment

Score: 5

Explanation: The document is neutral overall, as it primarily reports a routine insider transaction. However, the late filing due to an administrative error is a minor negative.

Negatives

• The transaction was reported late due to an administrative error, indicating a potential lapse in internal controls.

Risks

• The late filing of the transaction could raise concerns about the company's internal controls and compliance procedures.
• Administrative errors in reporting insider transactions could lead to regulatory scrutiny.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. The late filing, however, is not typical and may raise some concerns.

Comparison to Industry Standards

• Form 4 filings are a standard requirement for publicly traded companies in the US, and the information provided is consistent with what is expected.
• The late filing is not consistent with industry best practices, where timely reporting of insider transactions is crucial for maintaining market transparency and investor confidence.
• Companies like Amgen, Gilead, and Regeneron, which are also in the biotech sector, are expected to file these forms on time.

Related Party Transactions

• The transaction was a direct purchase from the issuer, Theravance Biopharma, under the company's equity incentive plan.

Stakeholder Impact

• The late filing may cause some concern among shareholders regarding the company's internal controls.
• The transaction itself is not expected to have a significant impact on other stakeholders.

Key Dates

Keywords

insider trading, share acquisition, equity incentive plan, Form 4, Theravance Biopharma, CEO, Rick E. Winningham